Business Description
Walvax Biotechnology Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE100000WN2
Share Class Description:
SZSE:300142: Class ACompare
Compare
Traded in other countries / regions
300142.China IPO Date
2011-03-10Description
Walvax Biotechnology Co Ltd biological pharmaceutical enterprise engaged in research and development, production and sales of bio-medicine products. It offers bio-medicines, such as vaccines, blood products, and others. The company's products include Haemophilus influenza type b conjugate vaccines, freeze-dried group A, C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines, and group A and C meningococcal polysaccharide vaccines.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.11 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | 1.77 | |||||
| Interest Coverage | 119.64 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 4.54 | |||||
| Beneish M-Score | -2.77 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.9 | |||||
| 3-Year EBITDA Growth Rate | -15.7 | |||||
| 3-Year EPS without NRI Growth Rate | -7.9 | |||||
| 3-Year Book Growth Rate | 11.2 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.21 | |||||
| 9-Day RSI | 43.41 | |||||
| 14-Day RSI | 39.27 | |||||
| 6-1 Month Momentum % | -26.6 | |||||
| 12-1 Month Momentum % | -49.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.85 | |||||
| Quick Ratio | 2.48 | |||||
| Cash Ratio | 1.38 | |||||
| Days Inventory | 678.42 | |||||
| Days Sales Outstanding | 315.01 | |||||
| Days Payable | 1206.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.07 | |||||
| Dividend Payout Ratio | 0.02 | |||||
| 3-Year Dividend Growth Rate | -20.6 | |||||
| Forward Dividend Yield % | 0.07 | |||||
| 5-Year Yield-on-Cost % | 0.07 | |||||
| 3-Year Average Share Buyback Ratio | -1.3 | |||||
| Shareholder Yield % | -0.93 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 84.89 | |||||
| Operating Margin % | 24.83 | |||||
| Net Margin % | 6.74 | |||||
| FCF Margin % | 0.14 | |||||
| ROE % | 2.78 | |||||
| ROA % | 1.68 | |||||
| ROIC % | 8.14 | |||||
| ROC (Joel Greenblatt) % | 8.79 | |||||
| ROCE % | 3.67 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 87.85 | |||||
| PE Ratio without NRI | 32.4 | |||||
| Shiller PE Ratio | 84.96 | |||||
| PEG Ratio | 7.9 | |||||
| PS Ratio | 5.91 | |||||
| PB Ratio | 2.46 | |||||
| Price-to-Tangible-Book | 2.93 | |||||
| Price-to-Free-Cash-Flow | 4773.33 | |||||
| Price-to-Operating-Cash-Flow | 26.77 | |||||
| EV-to-EBIT | 41.75 | |||||
| EV-to-EBITDA | 41.75 | |||||
| EV-to-Revenue | 4.88 | |||||
| EV-to-FCF | 3481.23 | |||||
| Price-to-Projected-FCF | 4.98 | |||||
| Price-to-Median-PS-Value | 0.22 | |||||
| Price-to-Graham-Number | 2.05 | |||||
| Price-to-Net-Current-Asset-Value | 9.31 | |||||
| Earnings Yield (Greenblatt) % | 2.4 | |||||
| FCF Yield % | 0.02 | |||||
| Forward Rate of Return (Yacktman) % | 2.79 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Walvax Biotechnology Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 3,880.259 | ||
| EPS (TTM) (Â¥) | 0.163 | ||
| Beta | 0.52 | ||
| Volatility % | 38.09 | ||
| 14-Day RSI | 39.27 | ||
| 14-Day ATR (Â¥) | 0.561273 | ||
| 20-Day SMA (Â¥) | 14.704 | ||
| 12-1 Month Momentum % | -49.8 | ||
| 52-Week Range (Â¥) | 13.13 - 32.23 | ||
| Shares Outstanding (Mil) | 1,607.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Walvax Biotechnology Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Walvax Biotechnology Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Walvax Biotechnology Co Ltd Frequently Asked Questions
What is Walvax Biotechnology Co Ltd(SZSE:300142)'s stock price today?
The current price of SZSE:300142 is ¥14.33. The 52 week high of SZSE:300142 is ¥32.23 and 52 week low is ¥13.13.
When is next earnings date of Walvax Biotechnology Co Ltd(SZSE:300142)?
The next earnings date of Walvax Biotechnology Co Ltd(SZSE:300142) is .
Does Walvax Biotechnology Co Ltd(SZSE:300142) pay dividends? If so, how much?
The Dividend Yield %  of Walvax Biotechnology Co Ltd(SZSE:300142) is 0.07% (As of Today), Highest Dividend Payout Ratio of Walvax Biotechnology Co Ltd(SZSE:300142) was 0.36. The lowest was 0.02. And the median was 0.07. The  Forward Dividend Yield % of Walvax Biotechnology Co Ltd(SZSE:300142) is 0.07%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers